Immune checkpoint inhibitors, such as monoclonal antibodies targeting programmed death
1 (PD-1) and programmed death ligand-1 (PD-L1), have achieved enormous success in the …

The advent of immune checkpoint inhibitors has revolutionized cancer therapy by leveraging
the body's immune system to combat malignancies effectively. Among these groundbreaking …

Expression of programmed death-ligand 1 (PD-L1) is frequently observed in human
cancers. Binding of PD-L1 to its receptor PD-1 on activated T cells inhibits anti-tumor …

The immunosuppressive molecule programmed death-ligand 1 (PD-L1) is frequently
upregulated in human cancers. Binding of PD-L1 to its receptor, programmed death-1 (PD …

The programmed death-1 receptor (PD-1) acts as a T-cell brake, and its interaction with
ligand-1 (PD-L-1) interferes with signal transduction of the T-cell receptor. This leads to …

Programmed cell death receptor 1 (PD-1) and its ligand, PD-L1, are important immune
checkpoint proteins. Although antibodies that block PD-1/PD-L1 have shown promising …

ABSTRACT Programmed death-1 (PD-1) is a cell surface receptor that functions as a T cell
checkpoint and plays a central role in regulating T cell exhaustion. Binding of PD-1 to its …

Interference of the binding of programmed cell death protein 1 (PD-1) and programmed
death-ligand 1 (PD-L1) has become a new inspiring immunotherapy for resisting cancers …

Abstract Targeting the PD-1/PD-L1 immunologic checkpoint with monoclonal antibodies has
provided unprecedented results in cancer treatment in the recent years. Development of …

Antibodies targeting the PD-1/PD-L1 immune checkpoint achieved spectacular success in
anticancer therapy in the recent years. In contrast, no small molecules with cellular activity …